Table 4 Dose modifications among patients receiving any LTP treatment
|  | Overall (N = 121) | US (n = 34) | Canada (n = 33) | Germany (n = 13) | Australia (n = 19) | UK (n = 21) | Italy (n = 1) |
|---|---|---|---|---|---|---|---|
Patients with any dose modification | 42 (34.7) | 15 (44.1) | 13 (39.4) | 2 (15.4) | 4 (21.1) | 8 (38.1) | 0 |
Patients with any up-dosinga | 30 (24.8) | 10 (29.4) | 13 (39.4) | 0 | 2 (10.5) | 5 (23.8) | 0 |
Berinert® | n = 31 | n = 2 | n = 17 | n = 4 | n = 7 | n = 1 | n = 0 |
 Dose modification | 8 (25.8) | 0 | 6 (35.3) | 0 | 2 (28.6) | 0 | NA |
 Up-dosing | 8 (25.8) | 0 | 6 (35.3) | 0 | 2 (28.6) | 0 | NA |
Cinryze® | n = 36 | n = 21 | n = 6 | n = 7 | n = 0 | n = 2 | n = 0 |
 Dose modification | 13 (36.1) | 12 (57.1) | 1 (16.7) | 0 | NA | 0 | NA |
 Up-dosing | 9 (25.0) | 8 (38.1) | 1 (16.7) | 0 | NA | 0 | NA |
Danazol | n = 65 | n = 15 | n = 19 | n = 2 | n = 11 | n = 18 | n = 0 |
 Dose modification | 21 (32.3) | 4 (26.7) | 6 (31.6) | 1 (50.0) | 2 (18.2) | 8 (44.4) | NA |
 Up-dosing | 13 (20.0) | 2 (13.3) | 6 (31.6) | 0 | 0 | 5 (27.8) | NA |
Tranexamic acid | n = 15 | n = 0 | n = 5 | n = 0 | n = 7 | n = 2 | n = 1 |
 Dose modification | 3 (20.0) | NA | 3 (60.0) | NA | 0 | 0 | 0 |
 Up-dosing | 3 (20.0) | NA | 3 (60.0) | NA | 0 | 0 | 0 |
Lanadelumab | n = 11 | n = 7 | n = 0 | n = 4 | n = 0 | n = 0 | n = 0 |
 Dose modification | 1 (9.1) | 0 | NA | 1 (25.0) | NA | NA | NA |
 Up-dosing | 0 | NA | 0 | 0 | NA | NA | NA |